Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share.
Copaxone (glatiramer acetate)
By far Teva’s biggest selling drug, Copaxone has received challenges from generic makers Sandoz, Momenta, Mylan and Natco all vying to launch their own versions of the multiple sclerosis drug.
In an effort to extend the life of the drug, which is worth $4.3 billion a year, Teva formulated a new formulation for the drug, which was approved by the US Food and Drug Administration (FDA) in January.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Pharmaceutical patents, expiry, product exclusivity, generics, Nexium